BBNX Stock Forecast & Price Target

Beta Bionics is supported by a differentiated closed-loop insulin delivery platform that is already gaining share, with about 13k global users as of YE24 and 1Q26 revenue of $27.6MM beating expectations while gross margin improved to 59.5%. Its outlook is strengthened by a steady pattern of beats and raises, expanding pharmacy-channel penetration, and management’s raised 2026 gross margin guidance to 57.5%-59.5%, which should support a more durable earnings base. The newly FDA-cleared Mint patch pump adds a meaningful growth catalyst, with 1Q27 launch timing, capacity for 1.5M+ units in FY27, and higher 2027-2028 revenue forecasts reflecting accelerated patient starts and broader commercialization.

Beta Bionics is negative because, despite a strong Q1 with revenue of $27.6M, gross margin of 59.5%, and an adjusted EBITDA loss of $17.7M that beat expectations, management still cut 2026 sales guidance to $121M-$126M from $131M-$136M. The lower outlook reflects roughly $10M of revenue deferred from 4Q into 2027 as patients wait for Mint, while Mint’s initial sub-scale margins should pressure near-term profitability and push full-year 2026 adjusted EBITDA further to -$79.9M. More broadly, the stock faces execution risk from competition, pharmacy-channel adoption, regulatory issues, and possible dilution, all of which could limit sustained share gains and margin recovery.